Up-Front Deal Economics May Not Match Drugs’ Likelihood Of Approval
Executive Summary
In earlier development phases, most of the therapeutic classes with higher approval rates tend on average to have the larger up-front alliance payments. But in Phase III, licensees are paying top dollar for candidates in areas with the lowest likelihoods of approval.